JPRN-jRCT2031220210进行中（未招募）3 期
A phase III, open label study of FPF3401 in patients with hyposelenemia
rabe Hiromi0 个研究点目标入组 53 人开始时间: 2022年7月9日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 6month old 至 ot applicable（—）
- 性别
- All
入选标准
- •Previously untreated patients
- •1)Patients with hyposelenemia or suspected hyposelenemia.
- •2)Patients having capability of intestinal absorption of selenium.
- •3)Patients on enteral nutrition therapy or diet therapy.
- •4)Patients with serum selenium concentrations below the reference value.
- •High-dose treatment patients
- •1)Patients with hyposelenemia or suspected hyposelenemia.
- •2)Patients daily treated with high-dose selenium preparations by oral or tube administration.
- •3)Patients having capability of intestinal absorption of selenium.
排除标准
- •Previously untreated patients
- •1)Patients mainly treated with their nutrition intravenously.
- •2)Patients treated with any of the following drugs.
- •(1)Selenium preparations
- •(2)Teduglutide
- •3)Patients allergic to selenium.
- •High-dose treatment patients
- •1)Patients treated with any of the following drugs.
- •(1)Selenium preparations (except for oral or tube administration)
- •(2)Teduglutide
- •2)Patients allergic to selenium.
研究者
相似试验
进行中（未招募）
3 期
A Phase 3study of FF-31501 in meniscus tear patientsMeniscus injuries indicated for meniscectomyJPRN-jRCT2073220083Sakurai Tsutomu18
进行中（未招募）
1 期
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.EUCTR2017-001290-17-PLF2G Biotech GmbH (FN 483749 x)200
进行中（未招募）
1 期
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.EUCTR2017-001290-17-ESF2G Ltd.,100
进行中（未招募）
1 期
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.EUCTR2017-001290-17-NLF2G Biotech GmbH (FN 483749 x)200
进行中（未招募）
1 期
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.EUCTR2017-001290-17-GBF2G Biotech GmbH200